Literature DB >> 3733964

Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids.

H K Lim, J W Hubbard, K K Midha.   

Abstract

An enantioselective gas chromatographic quantitation assay was developed for the enantiomers of dl-threo-methylphenidate in plasma and urine. dl-threo-Methylphenidate and the internal standard were acylated with N-heptafluorobutyryl-1-prolylchloride under Schotten-Baumann conditions prior to gas chromatographic separation on achiral mixed stationary phases. The derivatives were detected by means of a nitrogen-phosphorus detector. Linear and reproducible calibration curves were obtained over the concentration ranges 0.43-43.25 and 2.16-216.25 ng/ml enantiomer in plasma or urine, respectively. This enantioselective gas chromatographic quantitation assay was applied in a single oral dose disposition study of dl-threo-methylphenidate in a healthy adult volunteer. Stereoselective differences were observed in the plasma concentration-time profiles and cumulative urinary excretion profiles following oral doses of 20 and 40 mg of dl-threo-methylphenidate hydrochloride. Only d-threo-methylphenidate was detectable in plasma after 4 h.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733964     DOI: 10.1016/s0378-4347(00)80704-5

Source DB:  PubMed          Journal:  J Chromatogr


  10 in total

1.  Optical purity determination of threo-methylphenidate hydrochloride using a chiral europium nuclear magnetic resonance (NMR) shift reagent.

Authors:  G M Hanna; C A Lau-Cam
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

2.  Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats.

Authors:  T Aoyama; H Kotaki; Y Sawada; T Iga
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn
Journal:  Drug Metab Dispos       Date:  2016-01-04       Impact factor: 3.922

Review 4.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

Authors:  Natalie L LeVasseur; Hao-Jie Zhu; John S Markowitz; C Lindsay DeVane; Kennerly S Patrick
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

7.  Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.

Authors:  T Aoyama; H Kotaki; T Sasaki; Y Sawada; Y Honda; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

9.  Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates.

Authors:  Xiaoxia Yang; Suzanne M Morris; Jeffery M Gearhart; Christopher D Ruark; Merle G Paule; William Slikker; Donald R Mattison; Benedetto Vitiello; Nathan C Twaddle; Daniel R Doerge; John F Young; Jeffrey W Fisher
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

10.  Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Authors:  Feng Liu; Haruka Minami; Raul R Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.